NASDAQ:LEGN - Legend Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $66.80
  • Forecasted Upside: 39.40 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$47.92
▼ -0.96 (-1.96%)

This chart shows the closing price for LEGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Legend Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LEGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LEGN

Analyst Price Target is $66.80
▲ +39.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $66.80, with a high forecast of $77.00 and a low forecast of $53.00. The average price target represents a 39.40% upside from the last price of $47.92.

This chart shows the closing price for LEGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Legend Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2022Morgan StanleyBoost Price TargetOverweight$55.00 ➝ $63.00Low
7/8/2022BMO Capital MarketsReiterated RatingBuy$77.00N/A
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$77.00High
3/15/2022BarclaysInitiated CoverageOverweight$53.00High
3/7/2022Morgan StanleyBoost Price TargetOverweight$51.00 ➝ $55.00Medium
3/1/2022BTIG ResearchBoost Price Target$65.00 ➝ $75.00High
1/31/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$51.00High
1/6/2022Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
12/21/2021Piper SandlerInitiated CoverageOverweight$66.00Medium
10/12/2021Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $51.00Low
10/8/2021BTIG ResearchBoost Price TargetBuy$55.00 ➝ $65.00High
6/29/2021JPMorgan Chase & Co.Reiterated RatingBuyLow
5/17/2021BTIG ResearchInitiated CoverageBuy$55.00High
4/19/2021Morgan StanleyLower Price TargetOverweight$55.00 ➝ $50.00Low
1/20/2021JPMorgan Chase & Co.Reiterated RatingBuyHigh
8/11/2020Jefferies Financial GroupReiterated RatingBuy$47.00Low
7/1/2020Jefferies Financial GroupInitiated CoverageBuy$47.00High
7/1/2020JPMorgan Chase & Co.Initiated CoverageOverweight$50.00High
6/30/2020Morgan StanleyInitiated CoverageOverweight$55.00High
(Data available from 8/11/2017 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/13/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/12/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
3/14/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/13/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/13/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
6/12/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 6 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/11/2022

Current Sentiment

  • 6 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Legend Biotech logo
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Read More

Today's Range

Now: $47.92
Low: $47.92
High: $49.10

50 Day Range

MA: $49.73
Low: $42.96
High: $57.10

52 Week Range

Now: $47.92
Low: $30.75
High: $58.00

Volume

2,449 shs

Average Volume

1,030,557 shs

Market Capitalization

$7.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Legend Biotech?

The following Wall Street analysts have issued stock ratings on Legend Biotech in the last twelve months: Barclays PLC, BMO Capital Markets, BTIG Research, Morgan Stanley, and Piper Sandler.
View the latest analyst ratings for LEGN.

What is the current price target for Legend Biotech?

5 Wall Street analysts have set twelve-month price targets for Legend Biotech in the last year. Their average twelve-month price target is $66.80, suggesting a possible upside of 36.1%. BMO Capital Markets has the highest price target set, predicting LEGN will reach $77.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $53.00 for Legend Biotech in the next year.
View the latest price targets for LEGN.

What is the current consensus analyst rating for Legend Biotech?

Legend Biotech currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LEGN will outperform the market and that investors should add to their positions of Legend Biotech.
View the latest ratings for LEGN.

What other companies compete with Legend Biotech?

How do I contact Legend Biotech's investor relations team?

Legend Biotech's physical mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The company's listed phone number is 732-317-5050 and its investor relations email address is [email protected] The official website for Legend Biotech is www.legendbiotech.com. Learn More about contacing Legend Biotech investor relations.